Abbott’s CardioMEMS system includes a wireless blood pressure sensor placed within the pulmonary artery, to catch early signs of worsening heart failure. Previously any changes were monitored remotely by clinicians, who could then adjust medication doses or make lifestyle recommendations.
By using the company’s CardioGuide HF smartphone app, patients will be able to track their own pulmonary artery pressure trends and receive new drug regimens through a pre-established dynamic treatment plan.
According to Abbott, heart failure can progress before patients develop noticeable symptoms such as shortness of breath or swelling. The company said it aims to help patients take a more active role and stay connected with their doctor between visits. It plans to roll out the software updates later this year.
This past June, Abbott launched its latest external data recorder for the CardioMEMS system. The Hero device is about the size of a laptop case, and includes Wi-Fi and cellular connectivity for taking readings.
CardioMEMS received a broader FDA heart failure approval in 2022, following its first green light in 2014.
